Does metformin have a “buffer effect” on serum TSH levels in euthyroid diabetic patients?

Silvia Santos-Palacios,1 Antonio Brugos-Larumbe,2 Francisco Guillén-Grima,3 Ane Garmendia-Madariaga,4 Juan C. Galofré1

1Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, University of Navarra, 2Department of Health Sciences, Public University of Navarra, 3Department of Preventive Medicine, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain, 4Department of General Surgery, Spital Zollikerberg, Zürich, Switzerland

ABSTRACT

OBJECTIVE: In the last few years a number of studies have found that metformin has a thyrotropin (TSH)-lowering effect in patients with type 2 diabetes (DM2) and that this effect disappears after discontinuation of the drug. Initial studies were carried out in hypothyroid patients on levothyroxine (LT4) treatment. However, this effect was observed only when serum TSH levels were elevated. The aim of this study was to assess the effect of metformin treatment on serum TSH levels in euthyroid DM2 patients. DESIGN: A retrospective study was conducted in seven primary health care centers in Spain. The study included 278 DM2 patients (110 females). Serum TSH level was tested before and one year after the onset of metformin treatment. We compared both TSH levels by paired t-tests. The sample was divided into four hierarchical clusters (C1 to C4), according to the Euclidean distance of the initial TSH level. No patient received LT4 treatment. RESULTS: Pre-metformin serum TSH level (2.00±0.76 mU/L) was statistically significantly lower than post-metformin level (2.20±0.87 mU/L; P<0.001). Interestingly, this trend was observed only in clusters 1 and 2 (those with lower baseline TSH levels), whereas the trend was lost in clusters 3 and 4. The difference between pre- and post-metformin TSH levels follows a mathematical model. According to this model, the TSH threshold point level is 3.00 mU/L. CONCLUSION: Metformin seems to induce a “buffer effect” on TSH secretion in euthyroid diabetic individuals. Hence, our study found an unreported TSH behavior after metformin treatment.

Key words: Metformin, Thyroid, Thyrotropin, Type 2 diabetes

INTRODUCTION

Type 2 diabetes mellitus (DM2) and thyroid dysfunction are the two most prevalent endocrine disorders.1,2 In addition, the prevalence of thyroid dysfunction in DM2 patients is higher than in the general population.3,4
Metformin is considered the first choice as an oral agent for individuals with DM2 and may also be prescribed when insulin resistance is present in women with polycystic ovarian syndrome (PCOS). The TSH-lowering effect of metformin in DM2 patients with primary hypothyroidism was first reported by Vigersky et al in 2006. This effect was observed in both hypothyroid patients under levothyroxine (LT4) replacement therapy and in untreated subjects. Since then, several retrospective and prospective studies have confirmed this observation. While the majority of the initial studies were carried out on hypothyroid patients, other investigators recruited euthyroid subjects yielding, however, perplexing results. Furthermore, the aforementioned effect of metformin was also observed in hypothyroid women with coexistent PCOS.

Although the potential influence of LT4 therapy on the TSH-lowering effect of metformin in subjects under metformin treatment was ruled out in the previous studies, its presence could be misleading. Therefore, we decided to analyze a sample of patients not taking any thyroid hormone replacement. The available information led us to hypothesize that, to some extent, the metformin effect on TSH secretion could depend on the hormone circulating concentration. Hence, our study was designed to clarify this issue. We decided to evaluate the variation in serum TSH levels after one year of metformin treatment in a sample of DM2 patients with normal thyroid function. In our sample no patients were undergoing LT4 treatment.

SUBJECTS AND METHODS
We conducted a retrospective study in Navarra (northern Spain). DM2 patients on metformin treatment were recruited through the regional registry computerized database from seven primary health care centers. In these centers all the blood test results have been electronically compiled since 2004. Screening of thyroid function by evaluation of serum TSH level has been routinely performed on all individuals seeking medical advice in our region. Serum-free thyroxin (FT4) and thyroid autoantibodies levels are not routinely measured as part of the screening program, although they could be ordered at the discretion of the attending physician.

After obtaining the institutional approval of the Ethical Committee of the Public University of Navarra, we reviewed the electronic records of the selected Health Care Centers. We identified 4,007 DM2 patients taking metformin. Of the 4,007 potentially eligible patients, 406 patients had had a TSH determination before and after the onset of metformin treatment with one year apart in their follow-up. We rejected patients on LT4 treatment. Eventually we identified 278 euthyroid subjects (TSH within the reference range of 0.72-4.43 mU/mL) who satisfied the inclusion criteria for the study (Figure 1). The study was classified by the Spanish Medicine Agency (AEMPS) as an EPA-OD (Estudio Postautorización con Otros Diseños diferentes al de seguimiento prospectivo) with the code number ABL-MET-2013-01 on December 9, 2013.

The sample was further divided into hierarchical clusters (C1 to C4) for analysis according to the Euclidean distance of the initial (pre-metformin) TSH level. A dendrogram was performed to decide the number of clusters to be used.

![Figure 1. Flow chart of the study patients.](image-url)
Information regarding height, weight and blood pressure was also included in the study. Body mass index (BMI) was calculated as body weight (in kg) divided by the square of body height (in meters). Venous blood samples were drawn after 12 hours fasting in a baseline condition.

**Laboratory measurements**

Serum concentration of TSH was analyzed using a chemiluminescent immunoassay TSH3-Ultra (ADVIA Centaur® CP Immunoassay System). Inter-assay coefficient of variation is below 6%. TSH reference limits ranged between 0.72 and 4.43 mU/L, according to our findings in a previous study.17

**Statistical analyses**

Statistical analyses were performed using SPSS for Windows (version 17.0; SPSS, Inc., Chicago, IL, USA). Normal distributions were assessed with the Kolmogorov-Smirnov test, as well as skewness and kurtosis. The descriptive analysis was performed using mean and standard deviations for continuous normal variables or median values and 25th–75th percentiles for heavily skewed variables. Paired t-tests were used to analyze changes in TSH levels after metformin treatment. Groups were defined using cluster analysis. Linear regression analysis was performed to assess metformin effect on serum TSH level. P values were considered statistically significant when P < 0.05.

**RESULTS**

A total of 278 euthyroid diabetic individuals filled the inclusion criteria. The sample was divided into 4 clusters. The demographics and serum TSH levels (at baseline and post-metformin therapy) of the sample and clusters are displayed in Table 1.

Studied as a whole, and in contrast to what was expected, post-metformin serum TSH level was statistically significantly higher than the pre-metformin level (2.20±0.87 vs. 2.00±0.76 mU/L; P <0.001). However, the analysis by clusters revealed that this trend was observed only in clusters 1 and 2 (those with lower basal TSH levels), whereas this trend was lost in clusters 3 and 4 (those with the lowest number of patients: 32 and 13 patients, respectively) (Table 1 and Figure 2).

The analysis of the changes in TSH level depicted similar results in both genders. In males they varied from 1.93±0.74 to 2.13±0.85 mU/L, P <0.001, and in females from 2.11±0.79 to 2.31±0.90 mU/L, P <0.001 (Figure 3).

A linear regression model showed an inverse correlation between the basal and post-metformin serum TSH levels. The lower the initial TSH, the higher the TSH will be after metformin treatment (Figure 4). The difference between post-metformin and pre-metformin serum TSH level is explained by the following mathematical model: Difference (Post-Previous) = 0.607 – 0.204 (baseline TSH); P <0.001. The variation from basal to post-metformin serum TSH level was more than 40% in 19.8% of euthyroid subjects.

<table>
<thead>
<tr>
<th>Table 1. Clinical and biochemical data of euthyroid diabetic patients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Euthyroid Diabetic Patients</strong></td>
</tr>
<tr>
<td>All</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>Patients (N)</td>
</tr>
<tr>
<td>Gender M/F [N (%)]</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>BMI</td>
</tr>
<tr>
<td>Pre-metformin TSH</td>
</tr>
<tr>
<td>Post-metformin TSH</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD or as a percentage (%). N, number of patients. M, males. F, females. BMI (kg/m²), body mass index. TSH (mU/L) reference range: 0.72-4.43. Difference between pre-metformin and post-metformin serum TSH levels: * P <0.01; ** P = 0.19; * P = 0.33.
DISCUSSION

The results of the present retrospective study suggest that metformin treatment shifts circulating TSH concentration away from both ends of the spectrum of the reference range in euthyroid DM2 patients. We found a slight but significant increase of TSH level when TSH was in the lower-normal range, whereas a slight, although insignificant decrease, was observed when it was in the upper-normal range. We note that clusters 3 and 4 had the lowest number of patients (32 and 13, respectively) and this circumstance might affect the result and its significance. This unreported TSH behavior after metformin treatment is what we have dubbed the metformin “buffer effect”, since it seems that metformin induces in circulating TSH a return to the middle of the normal range.
Some previous studies have reported the absence of apparent changes in TSH levels after metformin treatment in euthyroid subjects.\textsuperscript{11,13,16-20} Our results are in contrast with these previous findings and we believe that the discrepancy could be explained by the difference in the study design. A prospective study by the Cappelli group examined 54 euthyroid patients with DM2.\textsuperscript{11} In this particular population metformin did not have a significant effect on serum TSH level, suggesting that metformin has a neutral effect on TSH in euthyroid individuals. Furthermore, a recent study of 828 DM2 patients with normal thyroid function by Diez & Iglesias in Spain with a cross-sectional design did not bear out a relationship between TSH values and metformin treatment in euthyroid DM2 patients.\textsuperscript{13} Rezzónico et al included only women with insulin resistance and thyroid nodules.\textsuperscript{18} Oleandri et al selected a short sample of 28 subjects with abdominal obesity and their patients were treated with metformin for a short period of 3 months.\textsuperscript{19} The published meta-analysis\textsuperscript{20} found no change in TSH levels in euthyroid patients, but was based only on the 2009 Cappelli study.\textsuperscript{11}

The results of our study are consistent with those of Cappelli et al published in 2012.\textsuperscript{12} In this second paper they designed a large retrospective study analyzing 393 DM2 patients. They corroborated the metformin-lowering TSH effect on subjects with high-normal basal serum TSH levels and on hypothyroid patients as well. These controversial findings clearly indicated the need for an in-depth analysis to explain the difference. Our suggested metformin “buffer effect” could help to explain the discrepancy, indicating that the investigators need to thoroughly dissect their data. It seems that not all “normal range” values are equally “normal”.

The difference between pre- and post-metformin TSH levels follows a mathematical model. According to this model, the TSH cut-off point level is 2.98 mU/L. In other words, metformin will have a lowering effect on TSH in those individuals with a serum TSH level higher than 2.98 mU/L, whereas this effect will be the opposite when basal TSH level is lower than 2.98 mU/L. Therefore we assume that a cutoff of 3 mU/L can be established that separates the TSH trend of this metformin “buffer effect”.

Our sample accurately represents the general population of our region. The fact that we included all individuals who seek medical advice from several general health care centers minimizes the potential selection bias of the study. In order to validate our results, we also analyzed the changes in circulating TSH level one year apart in a control group of euthyroid patients free of metformin treatment. We found no differences in circulating pre- and post- TSH levels. Since obesity could be considered as a possible confounding factor, we additionally analyzed serum TSH levels in obese and non-obese patients and observed the same trend in both groups (data not shown).

The mechanism of the metformin TSH-lowering effect remains largely unknown.\textsuperscript{20} However, it has been speculated that metformin may modulate thyroid function at central and tissue level.\textsuperscript{21} Previous observations have described how complex and multifactorial the metformin action on TRH/TSH/T4 could be.\textsuperscript{9} Metformin may change the affinity of and/or the number of thyroid hormone receptors, increase the dopaminergic tone in the pituitary or induce a constituent activation of the TSH receptor.\textsuperscript{9,21} It has also been proposed that metformin may have an inhibitory effect on hypothalamic AMPK activity which counteracts T3 effects at this level.\textsuperscript{22,23} In addition, metformin seems to improve peripheral thyroid function in both LT4-treated and LT4-untreated patients with hypothyroidism.\textsuperscript{20} The observation that the TSH-lowering effect of metformin also occurs in LT4-untreated hypothyroid patients excludes the possibility that the effect is due to an increased LT4 absorption in the gastrointestinal tract.\textsuperscript{20}

Although metformin-induced TSH changes seem to be small, this reduction could have a relevant impact on individuals with untreated subclinical hypothyroidism. This effect could also be relevant in obese euthyroid DM2 subjects, who normally have slightly increased TSH levels,\textsuperscript{17,24} in whom the use of metformin is indicated as treatment for insulin resistance.

In conclusion, our findings offer an insight into the effect of metformin on thyroid homeostasis which seems to be modulated according to the individual set point of circulating TSH levels. These data indicate that the repercussion of metformin treatment on serum TSH level in euthyroid DM2 patients resembles
a “buffer effect”. This could be of especial clinical relevance in euthyroid patients with serum TSH level in the normal-upper limit.

DECLARATION OF INTEREST

The authors declare that there is no conflict of interest.

FUNDING

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

REFERENCES